Catherine M. Pastor, Marie‐Reine Losser, Didier Payen – 1 November 1995 – Controversial studies have been published concerning the role of nitric oxide (NO) release (beneficial or deleterious) during sepsis. Severe hypotension has been treated by NO inhibitors in humans, but animal studies described an increased mortality rate with this treatment. We hypothesized that an NO donor might be beneficial in maintaining liver flow during endotoxemia.

Mitchell L. Shiffman, Lennox Jeffers, Jay H. Hoofnagle, Tommie Sue Tralka – 1 November 1995

W. Kenneth Washburn, W. David Lewis, Roger L. Jenkins – 1 November 1995 – Since January 1994, we have used percutaneous placement of both the subclavian and femoral cannulae to establish access for venovenous bypass during orthotopic liver transplantation. Percutaneous subclavian and femoral cannulae were used in 36 patients of which 5 had portal decompression by placement of a cannula in inferior mesenteric vein percutaneously through the abdominal wall.

Florence Wong, Laurence Blendis – 1 November 1995 – Background. Previous studies have suggested that the transjugular placement of an intrahepatic stent to establish a portosystemic shunt is an effective treatment of uncomplicated ascites accompanying variceal bleeding. We studied the stent shunt for use in patients with liver cirrhosis and ascites refractory to medical treatment.

Mei‐Hwei Chang, Hong‐Yuan Hsu, Hey‐Chi Hsu, Yen‐Hsuan Ni, Juei‐San Chen, Ding‐Shinn Chen – 1 November 1995 – To investigate the significance of spontaneous hepatitis B e antigen (HBeAg) seroconversion during childhood, 415 hepatitis B surface antigen (HBsAg) carrier children (ages 0 to 15 years) were prospectively followed for 7.1 ± 2.9 years. Hepatitis B virus (HBV) markers and liver function profiles of each child were tested at least once every 6 months. Among them, 50 were initially anti‐HBe positive and 140 seroconverted from HBeAg to anti‐HBe during follow‐up.

Michael Wilschanski, Peter Chait, Judy A. Wade, Lori Davis, Mary Corey, Patrick St. Louis, Anne M. Griffiths, Laurence M. Blendis, Stanley P. Moroz, Linda Scully, Eve A. Roberts – 1 November 1995 – The clinical presentation and outcome of 32 children with primary sclerosing cholangitis (PSC) are reviewed, the largest North American series. The majority of patients were diagnosed in their second decade (median age: 13 years). Four children presented before the age of 2 years, but none in the neonatal period.

Ruth Adler, Esther Hurwitz, Jack R. Wands, Michael Sela, Daniel Shouval – 1 November 1995 – Doxorubicin (adriamycin), once considered the treatment of choice for hepatocellular carcinoma (HCC), is known to cause cardiotoxicity and myelotoxicity. To reduce the systemic toxicity of adriamycin by direct delivery of the drug to the tumor site, we established a panel of monoclonal antibodies (MAbs) to hepatoma associated antigens that were conjugated to adriamycin by a dextran bridge.

Antonio Benedetti, Antonio di Sario, Gianluca Svegliati Baroni, Anne Marie Jezequel – 1 November 1995 – Transforming growth factor beta 1 (TGFβ1) is involved in promoting cell death by apoptosis in the liver, whereas the activation of Na+/H+ exchanger has been related to cell proliferation. The aim of this study was to gain information on the effects of TGFβ1 on intracellular pH and Na+H+ exchange activity in isolated periportal (PP) and perivenular (PV) rat hepatocytes using the pH‐sensitive dye BCECF in a perfused subconfluent hepatocyte monolayer.

Marijke van Oosten, Erika van de Bilt, Helga E. de Vries, Theo J. C. van Berkel, Johan Kuiper – 1 November 1995 – During sepsis the infiltration of leukocytes plays a pivotal role in tissue damage. Induction of septic shock results in an early accumulation of polymorphonuclear leukocytes in the liver (after 3 hours), which is followed by an infiltration of mononuclear phagocytes (after 30 hours). Expression of adhesion molecules may contribute to the migration of leukocytes to the site of inflammation.

Gotaro Yamada, Masahiro Takatani, Fumitoshi Kishi, Michiko Takahashi, Toshihiko Doi, Takao Tsuji, Sadahito Shin, Masashi Tanno, Mickey S. Urdea, Janice A. Kolberg – 1 November 1995 – To clarify the viral factors that may predict the therapeutic effect of interferon (IFN) in chronic hepatitis C (CHC) patients, we investigated the quantitative serum hepatitis C virus (HCV) RNA level, genotype, and liver biopsy histological features in 60 patients who were treated with 360 × 106 U of natural IFN‐α for 36 to 48 weeks and for more than 12 months after therapy.